Skip to content

Study · Not a test of the peptide alone · 2002

1 result

Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.

Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Aoki M, Yatsu T, Uchida W, Taniguchi N, Tanaka A

European journal of pharmacology1 Jun 2002Cited by 12 (Europe PMC)

PMID12098594 (opens in a new tab)DOI10.1016/s0014-2999(02)01813-7 (opens in a new tab)PepBankPUB-12098594
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 01LabNot a test of Oxytocin aloneIn vitro (cell-free)Activity measurement

    YM471, a vasopressin V1A/V2 antagonist, bound rat oxytocin receptors with a Ki of 31.0 nM, much lower affinity than for V1A and V2 receptors.

    In plain wordsIn lab tests, a vasopressin-blocking compound bound oxytocin receptors much more weakly than vasopressin receptors.

    Peptide
    Oxytocin
    Outcome
    Not applicableYM471 binding affinity (Ki) at the oxytocin receptor
    Study

    ratn: not reported in source

    Receptor binding with rat receptors
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    Ki
    31 nM
    YM471, rat oxytocin receptor

    Source sentences

    Summary
    YM471 exhibited much lower affinity for rat vasopressin V(1B) and oxytocin receptors, with K(i) values of 10.5 microM and 31.0 nM, respectively.
    1 context sentence
    Summary · context
    The pharmacologic profile of YM471 ((Z)-4'-[4,4-difluoro-5-[2-(4-dimethylaminopiperidino)-2-oxoethylidene]-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl]-2-phenylbenzanilide monohydrochloride), a novel potent vasopressin V(1A) and V(2) receptor antagonist, was investigated using several in vitro a…

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:53 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.